|
News Image

Why NYSE:PFE qualifies as a good dividend investing stock.

By Mill Chart

Last update: Sep 26, 2023

Our stock screener has spotted PFIZER INC (NYSE:PFE) as a good dividend stock with solid fundamentals. NYSE:PFE shows decent health and profitability. At the same time it gives a good and sustainable dividend. We'll dive into each aspect below.

Assessing Dividend Metrics for NYSE:PFE

ChartMill provides a Dividend Rating for every stock, ranging from 0 to 10. This rating assesses various dividend aspects, including yield, growth, and sustainability. NYSE:PFE earns a 8 out of 10:

  • With a Yearly Dividend Yield of 4.99%, PFE is a good candidate for dividend investing.
  • PFE's Dividend Yield is rather good when compared to the industry average which is at 3.87. PFE pays more dividend than 97.62% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 2.64, PFE pays a better dividend.
  • PFE has paid a dividend for at least 10 years, which is a reliable track record.
  • PFE has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.

Health Examination for NYSE:PFE

ChartMill assigns a proprietary Health Rating to each stock. The score is computed by evaluating various liquidity and solvency ratios and ranges from 0 to 10. NYSE:PFE was assigned a score of 5 for health:

  • The Altman-Z score of PFE (2.67) is better than 73.33% of its industry peers.
  • PFE has a Debt to FCF ratio of 6.13. This is amongst the best in the industry. PFE outperforms 84.76% of its industry peers.
  • A Current Ratio of 2.12 indicates that PFE has no problem at all paying its short term obligations.

What does the Profitability looks like for NYSE:PFE

Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NYSE:PFE has achieved a 8:

  • With an excellent Return On Assets value of 9.75%, PFE belongs to the best of the industry, outperforming 90.95% of the companies in the same industry.
  • PFE has a better Return On Equity (21.68%) than 91.90% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 11.96%, PFE belongs to the top of the industry, outperforming 90.00% of the companies in the same industry.
  • The 3 year average ROIC (16.16%) for PFE is well above the current ROIC(11.96%). The reason for the recent decline needs to be investigated.
  • PFE has a better Profit Margin (27.55%) than 94.76% of its industry peers.
  • With an excellent Operating Margin value of 31.21%, PFE belongs to the best of the industry, outperforming 95.71% of the companies in the same industry.
  • PFE's Operating Margin has improved in the last couple of years.
  • Looking at the Gross Margin, with a value of 68.78%, PFE is in the better half of the industry, outperforming 73.81% of the companies in the same industry.

Our Best Dividend screener lists more Best Dividend stocks and is updated daily.

For an up to date full fundamental analysis you can check the fundamental report of PFE

Disclaimer

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

Back

PFIZER INC

NYSE:PFE (11/30/2023, 6:53:54 PM)

After market: 30.67 +0.2 (+0.66%)

30.47

+0.39 (+1.3%)

PFE News

News Image44 minutes ago - CNBCCramer's Lightning Round: 'I'm not a buyer' of NIO

"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

News Image2 hours ago - Seeking AlphaFDA to decide on approving Keytruda/Padcev combo therapy by May 9 (NYSE:MRK)

The FDA has accepted Merck's (MRK) application for approval of its drug Keytruda in combination with Seagen (SGEN) and Astellas’s Padcev for the treatment of urothelial cancer.

News Image3 hours ago - Yahoo FinanceUPDATE 1-Pfizer is sued by Texas over COVID vaccine claims

Pfizer has been sued by Texas Attorney General Ken Paxton, who on Thursday accused the drugmaker of misrepresenting the efficacy of its widely-used COVID-19 vaccine. In a complaint filed in a Lubbock County state court, Paxton said it was misleading for Pfizer to claim its vaccine was 95% effective because it offered a "relative risk reduction" for people to who took it. Paxton said the claim was based on only two months of clinical trial data, and vaccine recipients' "absolute risk reduction" showed that the vaccine was just 0.85% effective.

News Image3 hours ago - The Sydney Morning Herald‘Pursuing justice’: Texas sues Pfizer for overstating COVID-19 vaccine effectiveness

The pharmaceutical giant sought to “intimidate and silence” those who questioned the product’s efficacy, the lawsuit alleges.

News Image4 hours ago - InvestorPlaceBillionaire Favorites: 3 Ultra-High Yield Stocks the Elite Love

Buying stocks simple for their high dividend yields is risky but these are three stocks the elite love regardless.

News Image4 hours ago - Yahoo FinancePfizer is sued by Texas over COVID-19 vaccine claims

Pfizer has been sued by Texas Attorney General Ken Paxton, who on Thursday accused the drugmaker of misrepresenting the efficacy of its widely-used COVID-19 vaccine. In a complaint filed in a Lubbock County state court, Paxton said it was misleading for Pfizer to claim its vaccine was 95% effective because it offered a "relative risk reduction" for people to who took it. Paxton said the claim was based on only two months of clinical trial data, and that the pandemic got worse even after people started taking Pfizer's vaccine.

News Image5 hours ago - SBWireAllergy Treatment Market Know Faster Growing Segments Now: Akorn, Pfizer, Novartis, Mylan N.V

Global Allergy Treatment Market Breakdown by Application (Hospitals, Specialty Clinics, Homecare, Others) by Type (Eye Allergy, Food Allergy, Skin Allergy, Asthma, Rhinitis, Others) by Treatment (Anti-Allergy Drugs, Immunotherapy) by Route of Administration (Oral, Inhalation, Intranasal, Others) and by Geography (North America, South America, Europe, Asia Pacific, MEA)

News Image6 hours ago - BloombergTexas Sues Pfizer for Overstating Covid-19 Vaccine Effectiveness

Texas Attorney General Ken Paxton accused Pfizer Inc. of misrepresenting the effectiveness of the company’s COVID-19 vaccine in a lawsuit filed in state court on Thursday.

News Image9 hours ago - Zacks Investment ResearchWhy Is Pfizer (PFE) Down 1.4% Since Last Earnings Report?

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

News Image9 hours ago - Market News VideoPFE January 2024 Options Begin Trading
News Image10 hours ago - Zacks Investment ResearchThe Zacks Analyst Blog Highlights AbbVie, J&J, Eli Lilly, Pfizer

AbbVie, J&J, Eli Lilly, Pfizer are included in this Analyst Blog.

News Image11 hours ago - CNBCCovid vaccine rates in the U.S. are slumping — and it will be a challenge to boost them

The one thing that experts, along with vaccine makers, can agree on is that low vaccination rates put people at risk of getting severe Covid infections.

PFE Links
Follow us for more